Cumulative incidence of sustained AKI in one year was 17.8% in the anti-VEGF group, which was similar with the one-year incidence of AKI (19.2%) in patients with metastatic colorectal cancer treated with chemotherapy combined with bevacizumab [14]. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.